Medifast (NYSE:MED) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen has downgraded Medifast (NYSE:MED) from a "hold" to a "sell" rating. The stock opened at $11.95, with a 52-week low of $11.25 and a high of $21.98. Medifast reported a loss of ($0.21) EPS for the last quarter, missing estimates, and had revenue of $89.41 million. Analysts predict a consensus target price of $16.50, with institutional investors holding 95.51% of the stock. Medifast's Q4 2025 guidance is set at -1.250 to -0.70 EPS.
Medifast (NYSE:MED - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.
- LifeMD Can Surge on Its GLP-1 Offerings
Separately, Weiss Ratings reiterated a "sell (d)" rating on shares of Medifast in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Medifast has an average rating of "Reduce" and a consensus target price of $16.50.
Check Out Our Latest Stock Report on MED
Medifast Price Performance
- LifeMD Shares Come Back to Life on GLP-1 Business Growth
Medifast stock opened at $11.95 on Friday. Medifast has a 52-week low of $11.25 and a 52-week high of $21.98. The stock has a fifty day moving average price of $13.35 and a two-hundred day moving average price of $13.52. The firm has a market capitalization of $131.34 million, a P/E ratio of 37.34 and a beta of 0.82.
Medifast (NYSE:MED - Get Free Report) last posted its earnings results on Monday, November 3rd. The specialty retailer reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.20). Medifast had a return on equity of 2.00% and a net margin of 0.76%.The firm had revenue of $89.41 million during the quarter, compared to the consensus estimate of $84.10 million. Medifast has set its Q4 2025 guidance at -1.250--0.70 EPS. On average, equities research analysts predict that Medifast will post 0.51 EPS for the current fiscal year.
Institutional Inflows and Outflows
- Are These Consumer Staples Too Cheap for Investors To Ignore?
Several institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its position in Medifast by 132.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 265,572 shares of the specialty retailer's stock valued at $3,580,000 after buying an additional 151,434 shares during the last quarter. Benjamin Edwards Inc. increased its position in Medifast by 75.0% in the first quarter. Benjamin Edwards Inc. now owns 24,419 shares of the specialty retailer's stock worth $329,000 after purchasing an additional 10,469 shares during the period. Nuveen LLC bought a new stake in Medifast during the 1st quarter worth about $407,000. Russell Investments Group Ltd. lifted its position in Medifast by 114.1% during the 1st quarter. Russell Investments Group Ltd. now owns 19,514 shares of the specialty retailer's stock valued at $267,000 after purchasing an additional 10,401 shares during the period. Finally, State of Wyoming boosted its stake in shares of Medifast by 184.1% in the 1st quarter. State of Wyoming now owns 32,137 shares of the specialty retailer's stock valued at $433,000 after purchasing an additional 20,825 shares during the last quarter. Institutional investors own 95.51% of the company's stock.
Medifast Company Profile
(Get Free Report)Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Featured Stories
- Five stocks we like better than Medifast
- What is a Death Cross in Stocks?
- OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever
- Manufacturing Stocks Investing
- 2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail
- What Is WallStreetBets and What Stocks Are They Targeting?
- CrowdStrike Partners With CoreWeave But Investors Sell the News
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Medifast Right Now?
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
